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S U M M A R Y
Objective: To evaluate the correlation between cytokine and neurotrophin expression and clinical
ﬁndings, disease severity, and outcome of children with H1N1 inﬂuenza infection.
Methods: A prospective observational clinical study was performed on 15 children with H1N1 infection,
15 controls with lower respiratory tract infections (LRTI), and 15 non-infected children. Plasma levels of
interleukin (IL)-1b, IL-6, and neurotrophic factor (nerve growth factor (NGF), brain derived neurotrophic
factor (BDNF), and glial derived neurotrophic factor (GDNF)) were measured using immunoenzymatic
assays.
Results: Signiﬁcantly higher levels of IL-1b, IL-6, BDNF, and NGF were detected in patients with H1N1
infection compared to LRTI controls, while there was no signiﬁcant variation in GDNF in the two groups.
IL-1b, IL-6, BDNF, and NGF levels were signiﬁcantly higher in H1N1 patients with more severe clinical
manifestations compared to H1N1 patients with mild clinical manifestations. Of note, IL-6 was
signiﬁcantly correlated with the severity of respiratory compromise and fever, while NGF up-regulation
was associated with the duration of cough. No correlation was found between interleukin and
neurotrophic factor expression and outcome.
Conclusions: H1N1 infection induces an early and signiﬁcant IL-1b, IL-6, BDNF, and NGF up-regulation.
The over-expression of these molecular markers is likely to play a neuroimmunomodulatory role in
H1N1 infection and may contribute to airway inﬂammation and bronchial hyper-reactivity in infected
children.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In recent years the world has faced a new pandemic caused by
an H1N1 inﬂuenza virus that contains a unique combination of
gene segments never before identiﬁed in humans or animals.1 This
new pandemic strain is of particular concern because of its efﬁcient
person-to-person transmission, responsible for increased viru-
lence and morbidity in humans.2
Infection with the H1N1 virus was identiﬁed as a cause of
febrile respiratory infections ranging from self-limited to severe
illness in both adults and children. A small percentage of children
develop more severe symptoms, such as elevated fever, persistent* Corresponding author. Tel.: +39 (0)6 30155203.
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http://dx.doi.org/10.1016/j.ijid.2013.07.006cough, pneumonia, and acute respiratory distress syndrome
(ARDS),3,4 requiring admission to the pediatric intensive care unit
(PICU) and mechanical ventilation.5
Several hypotheses to explain this particular virulence of H1N1 in
children have been advocated, including down-regulation of type 1
interferon expression, apoptosis, and hyperinduction of proinﬂam-
matory cytokines.6 Increased biosynthesis of inﬂammatory cyto-
kines, such as tumor necrosis factor alpha (TNF-a), interleukin (IL)-
1b, IL-6, and IL-10, and a cytokine-mediated inﬂammatory response,
has also been documented as responsible for the severity of different
viral lung infections, by increasing vascular permeability and
leukocyte accumulation in lung tissue.7–9
Studies conducted in experimental animal models suggest that
up-regulation of neurotrophins also plays a key role in the
inﬂammatory host response during viral lung infections.10 In
particular, respiratory syncytial virus (RSV) determines anses. Published by Elsevier Ltd. All rights reserved.
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derived neurotrophic factor (BDNF) in infected lungs.11 In contrast
to RSV infection, data regarding neurotrophin responses in other
types of inﬂuenza virus infection are limited. These studies have
produced contrasting results because both loss in hippocampal
expression of neurotrophic factors and NGF up-regulation in the
mouse model of inﬂuenza virus infection have been reported.12,13
NGF acts on the nociceptive ﬁbers innervating the lower
respiratory tract and increases the biosynthesis of proinﬂamma-
tory neurotransmitter substance P,14 and its high-afﬁnity receptor
(neurokinin 1) on inﬂammatory cells, leading to enhanced
neurogenic inﬂammation in infected lungs.15,16 NGF is also
involved in the sensitization of spinal circuitry that underlies
many forms of bronchiolar hyper-responsiveness, cough, and
asthma.17–19
BDNF is a neuropeptide involved in the central inﬂammatory
host response related to inﬂuenza virus infection.20 BDNF, together
with NGF, has been shown to be up-regulated in the lung cells
following chemical injury and virus-mediated inﬂammation, both
in experimental animal models and in infants with RSV
infection.21–23
However, the role of most cytokines and neurotrophins in
relation to clinical ﬁndings, disease severity, and the outcome of
patients with H1N1 virus infection has thus far remained unclear.
In an attempt to clarify their role in this infection and to better
characterize the blood proﬁle of these neurotrophins and
cytokines, we evaluated the plasma levels of IL-1b, IL-6, NGF,
BDNF, and glial derived neurotrophic factor (GDNF) in 15 children
with H1N1 infection, 15 controls with lower respiratory tract
infections (LRTI), and 15 non-infected children to determine
whether a correlation with the expression of these molecular
markers and clinical ﬁndings of patients exists.
2. Materials and methods
2.1. Study population
A prospective observational clinical study was conducted
among children admitted with a diagnosis of inﬂuenza H1N1
infection or LRTI to our pediatric department in Rome, Italy, from
October 2009 to December 2010. Patients with H1N1 inﬂuenza
virus infection were grouped according to age, chest radiograph
ﬁndings, clinical characteristics, respiratory care, and ﬁnal
outcome (Table 1). We also decided to group these patients into
two subgroups based on the severity of their symptoms: those
with severe manifestations of H1N1 infection and those with mild
manifestations. We considered severe manifestations of H1N1
infection to be the presence of hypoxia at admission (SpO2 less
than 80% in room air), ARDS requiring mechanical ventilation or
non-invasive ventilation (NIV) by helmet, oxygen supplementation
by Ventimask or continuous positive airway pressure (CPAP) by
face-mask, severity of fever (>39 8C at admission), duration of
cough, and, ﬁnally, the presence of speciﬁc radiological ﬁndings,
such as pneumothorax, pneumopericardium, and pneumomedias-
tinum (Table 1). Based on these admission parameters, nine
patients with severe manifestations of H1N1 inﬂuenza virus
infection were admitted to the PICU, while the other six patients
with mild symptoms of the disease were admitted to the pediatric
infectious disease unit (PIDU). Regarding the LRTI patients, eight
infants with severe RSV bronchiolitis were admitted to the PICU,
while the other seven children were admitted to the PIDU. Six
infants with RSV bronchiolitis admitted to the PICU underwent
oxygen supplementation and NIV by helmet, while the other two
patients required mechanical ventilation. The other seven infants
belonging to the control group required only symptomatic
treatment (Table 2).Oral oseltamivir (60 mg twice daily for 5 days) was adminis-
tered to all 15 patients with a diagnosis of inﬂuenza H1N1 and
supportive therapy was started based on the severity of respiratory
failure. All patients were isolated at admission based on their
clinical symptoms, suspected of H1N1 infection or another acute
respiratory illness. Throat/nose swabs and blood samples were
taken at admission, before the start of any treatment, for both
laboratory studies and cytokine/neurotrophic factor determina-
tion. All throat and nose swabs were sent to the microbiology
laboratory for detection (by culture and molecular tests) of
inﬂuenza A, B, and subtypes of A by inﬂuenza real-time reverse
transcriptase (RT)-PCR test, and for the detection of RSV,
adenovirus, parainﬂuenza viruses, and human metapneumovirus
infections; culture alone was used for the detection of bacteria. The
study was approved by the institutional review board, and the
parents of participating children were informed regarding the
study and provided written informed consent.
2.2. Statistical analysis
The non-parametric Mann–Whitney test and t-test were used
to perform statistical comparisons of continuous variables
between the children with H1N1 infection and the control group.
Analysis of variance was performed using the Tukey–Kramer test
to compare levels of IL-6, IL-1b, BDNF, NGF, and GDNF in the
studied population. Linear regression analysis was used to evaluate
the correlation between interleukin and neurotrophin expression
and clinical manifestations in H1N1 patients. The coefﬁcient of
determination (R2) was taken as a measure of the goodness of ﬁt of
the model. A p-value of <0.05 was considered signiﬁcant.
Statistical and database software used were GraphPad version
5.0 (GraphPad Software, San Diego, CA, USA) and Microsoft Ofﬁce
Excel 2007 (Microsoft Corporation, Redmond, WA, USA), respec-
tively.
3. Results
3.1. Clinical and laboratory differences between H1N1 patients, LRTI
controls, and ‘healthy children’
Fifteen patients with H1N1 virus infection, 15 controls with
LRTIs, and 15 non-infected children, deﬁned as ‘healthy children’,
were included in this study (see information on plasma sample
collection in the Supplementary Material). Patients with H1N1
infection were aged 1.1 to 4.3 years, with a mean age of 2.93 years;
LRTI controls were aged 11 months to 3.70 years, with a mean age
of 1.93 years; ‘healthy children’ were aged 14 months to 3.2 years,
with a mean age of 2.61 years (p = 0.36). Nine children with severe
H1N1 virus infection were admitted to our PICU due to the severity
of their respiratory compromise, while the other six patients were
admitted to the PIDU. Among the children with LRTIs, eight of 15
were admitted to the PICU with a diagnosis of severe RSV
bronchiolitis, while the other seven were admitted to the PIDU
(four with a diagnosis of non-RSV bronchiolitis and three with a
diagnosis of inﬂuenza A (H3N2) virus infection). Regarding clinical
differences between the two groups, H1N1 patients experienced
higher median fever (39.2 8C) compared to controls (37.7 8C)
(p < 0.0001). Cough was a common symptom in both groups.
However, H1N1 patients more frequently suffered from a dry and
longer cough compared to LRTI patients (median 6 days vs. 4 days;
p < 0.0001). The most frequent pulmonary abnormalities on chest
X-ray in the H1N1 patients were represented by pneumonia and
pulmonary consolidation, while in LRTI children we detected
atypical ﬁndings, such as hyperinﬂated lungs and segmental
pulmonary atelectasia. Two patients with H1N1 infection showed
pneumothorax, while another three children showed severe
Table 1
Patient demographic and clinical characteristics and respiratory care and complications in H1N1-infected children
Patient Age,
years
Fever at
ﬁrst day of
admission, 8C
Duration of
cough,
days
SpO2 at
admission
in room
air (%)
Chest X-ray Respiratory care Antimicrobial therapy Complications Length of stay in
hospital, days
Outcome
1 3.3 39.60.5 8 78 Pneumothorax O2 supplementation by Ventimask Ceftriaxone, clarithromycin,
oseltamivir
None 11 Good
2 2.5 39.70.4 6 78 Pneumonia CPAP by helmet (1 day) + O2 by Ventimask Ceftriaxone, oseltamivir None 10 Good
3 3.6 39.10.6 8 70 Interstitial pneumonia,
pleural effusion
NIV by full-face mask, EI/MV (2 days), CPAP
by helmet (4 days)
Ceftriaxone, clarithromycin,
oseltamivir
Pneumorrhachis 19 Good
4 2.1 39.30.6 6 80 Pneumonia O2 supplementation by Ventimask Ceftriaxone, oseltamivir None 9 Good
5 4.3 39.40.7 7 79 Bilateral pulmonary
inﬁltrates
O2 supplementation by Ventimask Ceftriaxone, oseltamivir, None 9 Good
6 3.4 39.20.4 7 50 Bilateral pulmonary
consolidation
EI/MV (11 days), CPAP by helmet (4 days) Ceftriaxone, clarithromycin,
oseltamivir
None 27 Good
7 2.8 39.70.6 6 76 Bilateral pulmonary
inﬁltrates
O2 supplementation by Ventimask Ceftriaxone, oseltamivir Seizures 11 Good
8 1.1 39.20.3 5 75 Pneumonia O2 supplementation by Ventimask Ceftriaxone, oseltamivir Pneumopericardium 18 Good
9 4.3 39.50.4 9 73 Pneumothorax,
bilateral pulmonary
consolidation
NIV by full- face mask Ceftriaxone, oseltamivir None 18 Good
10 2.4 38.50.5 7 90 Interstitial
pneumonia
O2 supplementation Clarithromycin, oseltamivir None 7 Good
11 2.3 38.70.2 4 92 Normal O2 supplementation Oseltamivir None 4 Good
12 3.8 38.20.4 5 94 Normal None Oseltamivir None 3 Good
13 3.3 38.30.7 5 95 Normal None Oseltamivir None 3 Good
14 1.9 38.40.6 6 91 Hyperinﬂated lung O2 supplementation Oseltamivir None 6 Good
15 1.5 38.10.4 6 93 Normal None Oseltamivir None 3 Good
CPAP, continuous positive airway pressure; EI, endotracheal intubation; MV, mechanical ventilation; NIV, non-invasive ventilation.
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Table 2
Patient demographic and clinical characteristics and respiratory assessment and complications in LRTI children
Patient Age,
years
Fever at ﬁrst day
of admission, 8C
Duration of cough,
days
SpO2 at admission
in room air (%)
Chest X-ray Respiratory care Antimicrobial therapy Complications Length of stay in
hospital, days
Outcome
1 1.5 37.40.3 4 74 Segmental pulmonary
atelectasia
CPAP by helmet and O2
supplementation
Amoxicillin None 7 Good
2 0.11 37.50.2 5 72 Segmental pulmonary
atelectasia and
hyperinﬂated lung
Mechanical ventilation and O2
supplementation
Amoxicillin, ceftriaxone None 6 Good
3 1.6 38.10.1 5 75 Hyperinﬂated lung O2 supplementation
by face mask
Amoxicillin None 5 Good
4 1.1 38.30.2 3 71 Hyperinﬂated lung CPAP by helmet
and O2 supplementation
Amoxicillin None 5 Good
5 1.3 37.40.4 4 80 Segmental pulmonary
atelectasia
CPAP by helmet
and O2 supplementation
Amoxicillin None 5 Good
6 1.4 37.20.6 3 78 Hyperinﬂated lung CPAP by helmet
and O2 supplementation
Amoxicillin None 5 Good
7 1.8 38.50.6 4 70 Hyperinﬂated lung Mechanical ventilation
and O2 supplementation
Clarithromycin,
amoxicillin
None 7 Good
8 1.1 38.10.3 5 75 Segmental pulmonary
atelectasia
CPAP by helmet
and O2 supplementation
Amoxicillin None 5 Good
9 3.10 37.50.2 4 91 Segmental pulmonary
atelectasia
O2 supplementation Amoxicillin None 3 Good
10 3.4 37.50.3 3 91 Interstitial pneumonia O2 supplementation Clarithromycin None 3 Good
11 3.7 37.70.5 4 88 Normal O2 supplementation Amoxicillin None 4 Good
12 2.3 37.50.3 3 93 Normal None Amoxicillin None 2 Good
13 2.3 38.10.4 3 90 Normal O2 supplementation Amoxicillin None 3 Good
14 1.2 38.30.6 3 92 Hyperinﬂated lung O2 supplementation Amoxicillin None 3 Good
15 3.1 37.80.5 4 93 Normal None Amoxicillin None 2 Good
LRTI, lower respiratory tract infection; CPAP, continuous positive airway pressure.
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Figure 1. Box plot showing the plasma levels of IL-1b, IL-6, BDNF, NGF, and GDNF in
H1N1 patients. The levels of IL-6 and BDNF were signiﬁcantly higher compared to
the other biomarkers evaluated (p < 0.0001).
Figure 2. Histogram showing the levels of IL-1b, IL-6, BDNF, NGF, and GDNF in
H1N1 patients (H1N1), LRTI controls (LRTI), and in ‘healthy children’ (HC).
Figure 3. Box plot showing the plasma levels of neurotrophins in patients and in
controls. H1N1 patients showed signiﬁcantly higher levels of BDNF (p < 0.0001)
and NGF (p < 0.0001) compared to LRTI controls. There were no signiﬁcant
differences in GDNF levels between the two groups (p = 0.7153).
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mediastinum, and pneumorrhachis on chest computed tomogra-
phy scan (Table 1). No pulmonary or systemic complications were
found in the LRTI group. No differences in clinical manifestations,
such as gastrointestinal and neurological symptoms, were found
between the two groups. Regarding laboratory tests (blood cell and
platelet counts, serum C-reactive protein, procalcitonin, alanine
aminotransferase, aspartate aminotransferase, creatinine, urea) no
signiﬁcant differences were detected between H1N1 patients and
LRTI controls. All children, both patients and controls, had a good
outcome without any signiﬁcant complications, however H1N1
patients had a signiﬁcantly longer duration of hospitalization
compared to the control group (median 9 days vs. 3 days;
p = 0.0013).
3.2. Interleukin and neurotrophic factor expression in H1N1 patients,
LRTI controls, and ‘healthy children’
We detected different plasma levels of both interleukins and
neurotrophic factors in H1N1 patients. In these patients we found
signiﬁcantly (p < 0.0001) higher levels of IL-6 (108.1  22.8 pg/ml)
compared to IL-1b (17.2  7.9 pg/ml) and BDNF (326.3  133.3 pg/
ml) compared to NGF (31.2  13.6 pg/ml) and GDNF (9.3  4.1 pg/ml)
(Figure 1). Also, in LRTI patients, the mean plasma levels of IL-6 were
signiﬁcantly higher compared to the levels of IL-1b (49.0  10.3 pg/
ml vs. 8.1  2.2 pg/ml) (p < 0.0001), while the mean plasma levels of
BDNF were signiﬁcantly higher compared to the levels of both NGF
and GDNF (BDNF 116.6  28.0 pg/ml; NGF 9.9  3.0 pg/ml; GDNF
9.8  3.3 pg/ml; p < 0.0001). Differently from H1N1 patients and LRTI
controls, we found no signiﬁcant differences between plasma levels of
interleukins and neurotrophins in ‘healthy children’. In these
children, the mean plasma levels of IL-6 and IL-1b were 3.1  0.3
pg/ml and 1.6  0.2 pg/ml, respectively (p = 0.49), while the levels of
BDNF, NGF, and GDNF were 5.8  2.6 pg/ml, 4.0  2.1 pg/ml, and
3.5  2.5 pg/ml, respectively (p = 0.52) (Figure 2). No signiﬁcant
correlations were found between interleukin and neurotrophic factor
expression and the age of H1N1 patients, LRTI controls, and ‘healthy
children’ (data not shown).
3.3. Plasma level differences in interleukin and neurotrophic factor
expression between H1N1 patients and controls
Signiﬁcantly higher levels of interleukin IL-6, IL-1b, BDNF, and
NGF were demonstrated in all patients with H1N1 infectioncompared to the controls, while GDNF levels did not vary
signiﬁcantly between the two groups. Compared with LRTI
patients, H1N1 patients displayed signiﬁcantly higher plasma
levels of IL-6 (108.1  22.8 pg/ml vs. 49.0  10.3 pg/ml; p < 0.0001)
and IL-1b (17.2  7.9 pg/ml vs. 8.1  2.2 pg/ml; p < 0.0002) (data not
shown). As shown in Figure 3, BDNF and NGF plasma levels were also
signiﬁcantly higher in H1N1 patients compared to children with
LRTIs. In H1N1 patients, the mean level of BDNF was 326.3  133.3
pg/ml, while in LRTI children, the BDNF mean level was 116.6  28.0
pg/ml (p < 0.0001). With regard to NGF levels, signiﬁcant differences
were detected between the two groups: in H1N1 patients, the mean
NGF level was 31.2  13.6 pg/ml, while in LRTI children, the mean
NGF level was 9.9  3.0 pg/ml (p < 0.0001) (Figure 3). No signiﬁcant
changes were observed in the GDNF plasma level between the two
groups (9.3  4.1 pg/ml in H1N1 patients compared to 9.8  3.3 pg/
ml in LRTI patients; p = 0.71).
3.4. Correlation between interleukin and neurotrophic factor
expression and disease severity and clinical manifestations in H1N1
patients
To elucidate the association between interleukin and neuro-
trophic factor expression and disease severity, we analyzed the
Figure 4. Box plot showing the plasma levels of interleukins in patients with H1N1
virus infections. H1N1 patients with more severe clinical manifestations of disease
elicited signiﬁcantly higher levels of IL-1b (p < 0.0001) and IL-6 (p < 0.0001)
compared to H1N1 patients with mild symptoms.
Figure 6. Scatter plot showing the signiﬁcant correlation between fever and IL-6
plasma levels in H1N1 patients. The line represents the regression line (linear
regression equation: fever = 0.02  IL-6 + 36.8; R2 = 0.64).
A. Chiaretti et al. / International Journal of Infectious Diseases 17 (2013) e1186–e1193 e1191plasma levels in patients with severe symptoms (nine patients)
and mild symptoms (six patients) of H1N1 inﬂuenza virus
infection. Compared to the mild symptoms patients, severe
symptoms H1N1 patients produced signiﬁcantly higher levels of
IL-1b (22.6  4.7 pg/ml vs. 9.1  2.8 pg/ml; p < 0.0001), IL-6
(124.1  11.8 pg/ml vs. 84.0  8.6 pg/ml; p < 0.0001), BDNF
(404.6  98.0 pg/ml vs. 208.8  82.6 pg/ml; p < 0.0015), and NGF
(38.4  12.7 pg/ml vs. 20.3  4.8 pg/ml; p < 0.0058), while no
statistical differences were found in GDNF plasma levels between
the two groups (8.1  3.9 pg/ml vs. 11.2  3.8 pg/ml, p = 0.152)
(Figures 4 and 5).
Moreover, to verify whether there was a correlation between
interleukin and neurotrophic factor up-regulation and clinical
manifestations in H1N1 patients, we compared the plasma levels
of these biomarkers with certain patient clinical symptoms. Of
note, we detected a positive correlation between plasma levels of
IL-6 and fever, with a coefﬁcient of determination of 0.64
(p = 0.0004) (Figure 6). We found the same positive correlation
between NGF plasma levels and the duration of cough, with aFigure 5. Box plot showing the plasma levels of neurotrophins in patients with
H1N1 virus infections. H1N1 patients with more severe clinical manifestations of
disease showed signiﬁcantly higher levels of BDNF (p = 0.0015) and NGF
(p = 0.0058) compared to H1N1 patients with mild symptoms. There were no
signiﬁcant differences in GDNF levels between the two groups (p = 0.1524).coefﬁcient of determination of 0.37 (p = 0.0165) (Figure 7).
Moreover, we detected the highest NGF plasma levels of all
H1N1 patients in two patients with speciﬁc pulmonary complica-
tions, such as pneumothorax and pneumopericardium (60.5 pg/ml
and 53.0 pg/ml, respectively). Finally, we found a negative
correlation between IL-6 plasma levels and SpO2 at admission in
room air, with a coefﬁcient of determination of 0.53 (p = 0.020)
(Figure 8). No signiﬁcant correlations were reported between
interleukin and neurotrophic factor expression and other param-
eters evaluated, such as biochemical markers of inﬂammation (C-
reactive protein and procalcitonin), systemic complications, and,
ﬁnally, the outcome of children with H1N1 virus infection.
4. Discussion
Our study, despite the limited patient sample, provides
evidence that H1N1 virus infection induces signiﬁcantly increased
plasma levels of both interleukins and neurotrophins soon after
virus lung infection, suggesting that these factors play a key role in
the molecular events leading to airway inﬂammation and disease
severity. Compared to LRTI controls and ‘healthy children’, H1N1-
infected children showed a strong up-regulation of IL-1b, IL-6,Figure 7. Scatter plot showing the signiﬁcant correlation between duration of cough
and NGF plasma levels in H1N1 patients. The line represents the regression line
(linear regression equation: duration of cough = 0.06  NGF + 4.5; R2 = 0.37).
Figure 8. Scatter plot showing the signiﬁcant correlation between SpO2 at
admission in room air and IL-6 plasma levels in H1N1 patients. The line represents
the regression line (linear regression equation: SpO2 = 0.38  IL-6 + 122.9;
R2 = 0.53).
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compromise assessed upon admission, while no differences were
detected in GDNF expression in the two patient groups. We also
observed that in H1N1 patients with more severe clinical
manifestations of disease, plasma levels of these interleukins
and neurotrophins were signiﬁcantly increased compared to those
of H1N1 patients with mild symptoms, and that this up-regulation
was correlated with some speciﬁc clinical manifestations and a
longer duration of hospitalization. In particular, IL-6 was
signiﬁcantly correlated with the severity of respiratory compro-
mise and higher fever, while NGF was correlated with the duration
of cough in this subset of patients.
To date it has been difﬁcult to fully elucidate the role of
interleukins and neurotrophins in the mechanisms of the virus–
host response, because both proinﬂammatory and immunopro-
tective actions have been reported. H1N1 virus infection causes the
activation of the host macrophages and lymphocytes determining
the release of proinﬂammatory cytokines and neuropeptides.6 The
increased biosynthesis of proinﬂammatory cytokines in the lung
tissue may lead to higher blood vessel permeability, phagocytic
cell recruitment, apoptosis of lung epithelial cells, and the release
of neutrophil-derived enzymes, such as myeloperoxidase and
elastase, responsible for the severity of acute lung injury after virus
infection.24,25
Cytokine up-regulation may also cause epithelial cell damage
by increasing the production of nitric oxide synthase and
cyclooxygenase, and by favoring the release of the excitatory
amino acids, as found in an experimental model of pulmonary
edema.26,27
Previous studies have reported the correlation between IL-1b
and IL-6 up-regulation and certain clinical and radiological
ﬁndings, such as fever, pneumonia, and ARDS, both in experimen-
tal animal models and in children with naturally acquired seasonal
inﬂuenza A.25,26,28 In particular, IL-1b and IL-6 have been
identiﬁed as speciﬁc markers of the severity of acute lung injury
during H1N1 inﬂuenza virus infection,7 and it has also been
reported that IL-1b is an early and useful marker of the severity
and progression of lung inﬂammation in patients undergoing
mechanical ventilation and unresponsive to antimicrobial treat-
ment.29 Our results are consistent with those of previous research,
because children with more severe clinical manifestations of H1N1
infection elicited a more intensive production of IL-1b and IL-6
than H1N1 patients with mild symptoms, suggesting that this up-regulation exerted a key role in the development of lung
inﬂammation.30,31
Our results also show that H1N1 patients produced higher
levels of BDNF and NGF than LRTI controls, conﬁrming the role of
these neurotrophins in the inﬂammatory host response after H1N1
infection. Of note, we also observed that in H1N1 patients with
more severe clinical manifestations of disease, plasma levels of
both these neurotrophins were signiﬁcantly increased compared
to those in H1N1 patients with mild symptoms, and that this up-
regulation was correlated with speciﬁc clinical manifestations,
such as the severity of pulmonary compromise and cough.
NGF, through its multiple actions on the airways and immune
and inﬂammatory cells, plays a key role in bronchiolar hyper-
responsiveness and cough.11,19,22,32 Recent studies have reported a
signiﬁcant correlation between cough and asthma and increased
NGF sputum levels, suggesting a strong relationship between NGF
up-regulation and the severity of airway hyper-responsive-
ness.33,34 It has also been reported that NGF enhances the
contractile responses of tracheal strips to histamine and neuro-
kinin A, both in experimental animal models and in humans with
viral lung infections, conﬁrming that this neurotrophin, either
alone or synergistically with BDNF, represents an essential link
between viral-infected epithelial cells and the sub-epithelial
neural networks.6,18,23,35,36 Our results are in keeping with this
evidence, because children with a longer duration of cough and
with speciﬁc pulmonary complications, such as pneumothorax and
pneumopericardium, elicited higher NGF and BDNF plasma levels
involved in the development of bronchial hyper-reactivity, lung
inﬂammation, and cough after H1N1 virus infection.
Until recently it has been difﬁcult to explain whether the
observed NGF and BDNF up-regulation in children with H1N1 virus
infection represents innate protective mechanisms for respiratory
cell survival or is secondary to a loss of physiological control of
neurotrophin/neurotrophin receptor biosynthesis. It is possible
that the biosynthesis of these neurotrophins occurs at the level of
infected structural cells of the respiratory airways, as well as
inﬂammatory cells stimulated by the H1N1 virus, such as activated
CD4 T lymphocytes.37,38 Available clinical and experimental data
do not permit a deﬁnitive clariﬁcation of these ﬁndings.
Neurotrophin plasma levels increase in several inﬂammatory
diseases, whereas up-regulation of TrkA/TrkB receptors has been
shown following different inﬂammatory stimuli, such as allergen
provocation and asthma. Recently lymphocytes, and in particular
activated T-cells, have been revealed to express BDNF and BDNF
receptors in the experimental animal model of pulmonary
sarcoidosis and chemical lung injury.39,40 So, it is possible that
neurotrophin up-regulation is secondary to rapid lymphocyte
activation by H1N1 virus infection and that this over-expression
represents an important process in the mechanisms of the
inﬂammatory host response after viral lung infections.23
In fact, previous studies have reported that different viral lung
infections are associated with early neurotrophin biosynthesis,
mainly BDNF and neurotrophin-3 (NT-3), suggesting that the
changes in neurotrophin release may contribute to the develop-
ment of lung inﬂammation and airway remodeling.23 In our study,
NGF and BDNF up-regulation, observed early after H1N1 virus
infection, is consistent with the timing of neurotrophin expression
found in an experimental model of virus-infected human alveolar
macrophages, suggesting that these neurotrophins act in a
different fashion to amplify and propagate inﬂammation in
infected airways.41
In conclusion, our observations provide new evidence that a
comprehensive neuroimmune response is activated at an early
stage in pandemic H1N1 inﬂuenza virus infection, with up-
regulated production of plasma interleukins IL-1b and IL-6 and
neurotrophins NGF and BDNF. These ﬁndings are consistent with
A. Chiaretti et al. / International Journal of Infectious Diseases 17 (2013) e1186–e1193 e1193previous experimental and clinical studies, conﬁrming a key
role for both interleukins and neurotrophins in the pathogen-
esis of airway inﬂammation and hyper-reactivity during viral
lung infections. The increased expression of interleukins and
neurotrophins may together be the underlying biochemical
cause of the observed clinical symptoms in H1N1 patients with
severe symptoms, and deﬁning the relationships between
interleukin and neurotrophic factor expression and the
pathophysiology of H1N1 may help to shed light on the
molecular aspects of H1N1 and other human viral lung
infections. Further clinical and experimental investigations
are necessary to identify the interleukin and neurotrophin
target cells in the damaged lung and to discover possible
clinical applications of these molecular markers in children
with H1N1 and other viral lung infections.
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